[go: up one dir, main page]

MX2020005462A - Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr). - Google Patents

Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).

Info

Publication number
MX2020005462A
MX2020005462A MX2020005462A MX2020005462A MX2020005462A MX 2020005462 A MX2020005462 A MX 2020005462A MX 2020005462 A MX2020005462 A MX 2020005462A MX 2020005462 A MX2020005462 A MX 2020005462A MX 2020005462 A MX2020005462 A MX 2020005462A
Authority
MX
Mexico
Prior art keywords
compounds useful
substituted indole
indole compounds
sub
compounds
Prior art date
Application number
MX2020005462A
Other languages
English (en)
Inventor
Alaric J Dyckman
Shoshana L Posy
Dharmpal S Dodd
Christopher P Mussari
Sreekantha Ratna Kumar
John L Gilmore
Trevor C Sherwood
Laxman Pasunoori
Tasir Shamsul Haque
Rushith Kumar Anumula
Brian K Whiteley
Srinivasan Kunchithapatham Duraisamy
Subramanya Hegde
Pitani Veera Venkata Srinivas
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020005462A publication Critical patent/MX2020005462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de la Fórmula (I) (ver Fórmula) N-óxidos, o sales de los mismos, en donde G, A, R1, R5 y n se definen aquí. También se describen métodos para usar tales compuestos como inhibidores de la señalización a través del receptor 7, u 8, o 9 tipo Toll, y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles en el tratamiento de enfermedades inflamatorias y autoinmunes.
MX2020005462A 2017-12-19 2018-12-18 Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr). MX2020005462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607472P 2017-12-19 2017-12-19
PCT/US2018/066149 WO2019126113A1 (en) 2017-12-19 2018-12-18 Substituted indole compounds useful as tlr inhibitors

Publications (1)

Publication Number Publication Date
MX2020005462A true MX2020005462A (es) 2020-09-07

Family

ID=65003586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005462A MX2020005462A (es) 2017-12-19 2018-12-18 Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).

Country Status (14)

Country Link
US (1) US11878975B2 (es)
EP (1) EP3728225B1 (es)
JP (1) JP7291145B2 (es)
KR (1) KR102742178B1 (es)
CN (1) CN111491930B (es)
AU (1) AU2018390820A1 (es)
BR (1) BR112020012084A2 (es)
CA (1) CA3085590A1 (es)
EA (1) EA202091474A1 (es)
ES (1) ES2932361T3 (es)
IL (1) IL275356A (es)
MX (1) MX2020005462A (es)
SG (1) SG11202005696YA (es)
WO (1) WO2019126113A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
BR112020011788A2 (pt) * 2017-12-19 2020-11-24 Bristol-Myers Squibb Company compostos 6-azaindóis
JP7291707B2 (ja) * 2017-12-20 2023-06-15 ブリストル－マイヤーズ スクイブ カンパニー アリールおよびヘテロアリール置換されたインドール化合物
KR102714788B1 (ko) * 2017-12-20 2024-10-08 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 아미노 인돌 화합물
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
JP7374130B2 (ja) 2018-06-05 2023-11-06 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患治療用の新規なテトラヒドロ－１Ｈ－ピラジノ［２，１－ａ］イソインドリルキノリン化合物
CN112313228A (zh) 2018-06-12 2021-02-02 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的新型杂芳基杂环基化合物
CN112584903B (zh) 2018-07-23 2025-12-23 豪夫迈·罗氏有限公司 用于自身免疫性疾病治疗的哌嗪化合物
CN112638908A (zh) 2018-09-04 2021-04-09 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的苯并噻唑类化合物
WO2020048596A1 (en) 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Novel pyrazolopyridine compounds for the treatment of autoimmune disease
EP3847170B1 (en) 2018-09-06 2022-06-22 F. Hoffmann-La Roche AG Novel cyclic amidine compounds for the treatment of autoimmune disease
EP3870589B1 (en) 2018-10-24 2023-09-06 Bristol-Myers Squibb Company Substituted indole dimer compounds
KR102839382B1 (ko) 2018-10-24 2025-07-25 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 및 인다졸 화합물
EP3965888B1 (en) * 2019-05-09 2024-08-21 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
ES2965164T3 (es) * 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
EP4051387B1 (en) 2019-10-31 2025-02-19 F. Hoffmann-La Roche AG Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
US12486273B2 (en) 2019-11-19 2025-12-02 Hoffmann-La Roche Inc. Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
EP4061821B1 (en) 2019-11-20 2025-08-06 F. Hoffmann-La Roche AG Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
EP4097084A4 (en) * 2020-01-30 2024-05-22 Anima Biotech Inc. COLLAGEN-1 TRANSLATION INHIBITORS AND METHODS OF USE
IL300727A (en) 2020-08-19 2023-04-01 Bristol Myers Squibb Co Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis
CN116075510A (zh) 2020-08-19 2023-05-05 百时美施贵宝公司 1H-苯并[d]咪唑衍生物作为TLR9抑制剂用于治疗纤维化
US20250002471A1 (en) * 2020-12-22 2025-01-02 Gilead Sciences, Inc. 6-substituted indole compounds
CN116783202A (zh) * 2021-02-09 2023-09-19 吉利德科学公司 噻吩并吡咯化合物
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
TWI849499B (zh) 2021-09-10 2024-07-21 美商基利科學股份有限公司 噻吩并吡咯化合物
IL314945A (en) * 2022-02-18 2024-10-01 Bristol Myers Squibb Co Substituted imidazopyridinyl compounds useful as inhibitors of tlr9
CN114591339B (zh) * 2022-05-10 2022-08-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
WO2025147320A1 (en) * 2024-01-03 2025-07-10 Kymera Therapeutics, Inc. Stat6 inhibitors and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
AU779117B2 (en) 1998-12-18 2005-01-06 Axys Pharmaceuticals, Inc. Protease inhibitors
DE60017179T2 (de) * 1999-10-19 2006-01-05 Merck & Co., Inc. Tyrosin kinaseinhibitoren
AU2003235741B8 (en) * 2002-01-07 2009-01-15 Eisai R&D Management Co., Ltd. Deazapurines and uses thereof
US7008958B2 (en) * 2002-05-21 2006-03-07 Bristol-Myers Squibb Company 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same
CN1798726A (zh) 2003-06-05 2006-07-05 麦克公司 取代吲哚及一种制备取代吲哚的方法
US7410975B2 (en) 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
CN101027051A (zh) * 2004-07-14 2007-08-29 Ptc医疗公司 治疗丙型肝炎的方法
AU2006324144A1 (en) 2005-01-28 2007-08-02 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
WO2006113458A1 (en) * 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
GB0602178D0 (en) * 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
JP2009532501A (ja) 2006-04-04 2009-09-10 ミリアド ジェネティクス， インコーポレイテッド 疾患および障害のための化合物
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008065198A1 (en) 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
US20100197657A1 (en) * 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
WO2010036905A1 (en) 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Benzoxazole compounds and methods of use
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
TR201809739T4 (tr) 2009-07-16 2018-07-23 Mallinckrodt Llc Toll benzeri reseptör 9 antagonistleri olarak (+)-morfinanlar ve bunların terapötik amaçlı kullanımları.
BR112012006630A2 (pt) 2009-09-24 2016-05-03 Hoffmann La Roche derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)
JP2013508414A (ja) 2009-10-22 2013-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症および他の慢性疾患の治療のための組成物
WO2012054862A2 (en) 2010-10-21 2012-04-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritis and related skin conditions
BR112013017947A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores de receptor toll-like
MX346387B (es) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
ES2583877T3 (es) 2011-06-01 2016-09-22 Janus Biotherapeutics, Inc. Moduladores novedosos del sistema inmunitario
CA2837227C (en) 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators
ES2602813T3 (es) 2011-06-09 2017-02-22 Rhizen Pharmaceuticals S.A. Nuevos compuestos como moduladores de GPR-119
AU2012285931B2 (en) 2011-07-15 2017-01-12 Cellzome Limited Novel substituted indole derivatives as gamma secretase modulators
US9873694B2 (en) 2011-10-04 2018-01-23 Janus Biotherapeutics, Inc. Imidazole quinoline-based immune system modulators
AU2013261267B2 (en) 2012-05-18 2017-06-29 Sumitomo Pharma Co., Ltd. Carboxylic acid compounds
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
EP3626717A1 (en) 2013-10-14 2020-03-25 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
CA2933466A1 (en) 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
AU2015303558B2 (en) 2014-08-15 2018-07-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrrolopyrimidine compounds used as TLR7 agonist
CN107108629A (zh) 2014-08-22 2017-08-29 贾纳斯生物治疗有限公司 新颖的n2, n4, n7, 6‑四取代的蝶啶‑2,4,7‑三胺和2, 4, 6, 7‑四取代的蝶啶化合物及其合成和使用方法
EP3072891A1 (en) 2015-03-24 2016-09-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. New Toll-Like Receptor 9 Antagonists
US10071079B2 (en) * 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EA038972B1 (ru) 2016-07-30 2021-11-16 Бристол-Маерс Сквибб Компани Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
MA46188A (fr) 2016-09-09 2019-07-17 Bristol Myers Squibb Co Composés indole substitués par pyridyle
ES2921020T3 (es) * 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
ES2909401T3 (es) 2017-08-04 2022-05-06 Bristol Myers Squibb Co Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9
US20210253593A1 (en) * 2017-11-14 2021-08-19 Bristol-Myers Squibb Company Substituted indole compounds

Also Published As

Publication number Publication date
ES2932361T3 (es) 2023-01-18
AU2018390820A1 (en) 2020-08-06
JP7291145B2 (ja) 2023-06-14
CN111491930B (zh) 2023-09-26
EP3728225A1 (en) 2020-10-28
WO2019126113A1 (en) 2019-06-27
IL275356A (en) 2020-07-30
BR112020012084A2 (pt) 2020-11-24
CN111491930A (zh) 2020-08-04
KR20200101402A (ko) 2020-08-27
EP3728225B1 (en) 2022-11-09
US11878975B2 (en) 2024-01-23
US20200308172A1 (en) 2020-10-01
JP2021506889A (ja) 2021-02-22
KR102742178B1 (ko) 2024-12-12
SG11202005696YA (en) 2020-07-29
CA3085590A1 (en) 2019-06-27
EA202091474A1 (ru) 2020-11-18

Similar Documents

Publication Publication Date Title
MX2020005462A (es) Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).
MX2020006168A (es) Compuestos de 4-azaindol.
MX2020005873A (es) Compuestos de 6-azaindol.
MX2020005515A (es) Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr).
MX2020006093A (es) Compuestos de indol eter sustituidos.
MX2020005622A (es) Compuestos de indol sustituidos con arilo y heteroarilo.
MX2020006014A (es) Compuestos de diazaindol.
MX2020005513A (es) Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
EA201990169A1 (ru) Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
MY196474A (en) [1,2,4]Triazolo[1,5-A]Pyridinyl Substituted Indole Compounds
ZA201906822B (en) Indole ahr inhibitors and uses thereof
JOP20200122A1 (ar) مركبات مفيدة لتثبيط cdk7
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
NZ747259A (en) Soluble c5ar antagonists
MX384087B (es) Piperidinas como inhibidores de menina.
JOP20190174B1 (ar) مثبطات jak1 انتقائية
UA115136C2 (uk) Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1
PH12018501413A1 (en) Substituted thiohydantoin derivatives as androgen receptor antagonists
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
MX2016011992A (es) Derivados de piperidina-diona.
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201590228A1 (ru) Антагонисты 5-ht3 рецептора
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
MX387920B (es) Peptidos antagonistas de prgc.